The conference will discuss the development of nucleic acid medicines including recent clinical successes, and current and upcoming challenges. By bringing together academics in basic and translational research and their peers in thriving biotechnology companies and promising start-ups, the conference aims to foster dialogue and to spearhead collaborations. The first day (December 9th, 2024) will cover the areas of RNA and DNA biology and preclinical therapeutics. The second day will discuss clinical translation of nucleic acid gene therapies and new technological developments from biotech companies. There will also be a career workshop and lunch with industry members and journal editors. The 3rd and final day will cover the topics of genome and epigenome editing and nucleic acid delivery mechanisms.

Bachem will attend in this event.